Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urine cytology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Urine cytology. Displaying page 2 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-004206-25 Sponsor Protocol Number: 1839IL/0711 Start Date*: 2005-03-02
    Sponsor Name:AstraZeneca AB
    Full Title: A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAP...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-003248-63 Sponsor Protocol Number: QBGJ398-302 Start Date*: 2020-02-19
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alt...
    Medical condition: Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10046731 Urothelial carcinoma urethra recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Prematurely Ended) BG (Prematurely Ended) PT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002646-16 Sponsor Protocol Number: 17000139BLC2001 Start Date*: 2021-04-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cance...
    Medical condition: Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    21.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004023-20 Sponsor Protocol Number: MK-3475-992 Start Date*: 2020-02-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Pa...
    Medical condition: Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IE (Completed) DK (Prematurely Ended) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005403-17 Sponsor Protocol Number: KH-MS-JAW-01 Start Date*: 2007-12-10
    Sponsor Name:GE Healthcare
    Full Title: A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma
    Medical condition: Upper urinary tract (ureters and pyela/renal pelvises) urothelial cell carcinoma for which blue light uretero-renoscopy and biopsies are performed for diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026431 Malignant neoplasm of renal pelvis and ureter transitional cell regional LLT
    9.1 10038497 Renal pelvis and ureter transitional cell cancer localized LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002050-78 Sponsor Protocol Number: NVALT-21 Start Date*: 2014-01-10
    Sponsor Name:NVALT
    Full Title: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced nonsmall cell lung cancer
    Medical condition: advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005241-45 Sponsor Protocol Number: MK3475-061 Start Date*: 2015-04-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after Fi...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) EE (Completed) ES (Completed) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000732-29 Sponsor Protocol Number: CA184-124 Start Date*: 2012-04-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab versus Pemetrexed in Subjects with Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed Afte...
    Medical condition: NSCLC is the description of a malign development of body tissues from cells in the Bronchia / Lungs where larger cells are visible per microscope.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002449-39 Sponsor Protocol Number: 42756493BLC2003 Start Date*: 2020-07-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Inva...
    Medical condition: Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) CZ (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001325-14 Sponsor Protocol Number: 580299/008 Start Date*: 2004-08-12
    Sponsor Name:GlaxoSmithKline SA
    Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit...
    Medical condition: cervical cancer => study is conducted in healthy female
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003653-30 Sponsor Protocol Number: NS-065/NCNP-01-211 Start Date*: 2021-06-08
    Sponsor Name:NS Pharma, Inc
    Full Title: A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Compared to Natural History Con...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004495-30 Sponsor Protocol Number: CYCLOIC-1 Start Date*: 2015-12-14
    Sponsor Name:Oulu University Hospital
    Full Title: Safety of intravesical bladder instillations among patients with severe interstitial cystitis
    Medical condition: Interstitial cystitis and bladder pain syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10071166 Bladder pain syndrome LLT
    18.1 10038359 - Renal and urinary disorders 10011796 Cystitis interstitial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-002067-18 Sponsor Protocol Number: B12CS-B13CS Start Date*: 2018-12-11
    Sponsor Name:Advicenne
    Full Title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses...
    Medical condition: Cystinuria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011778 Cystinuria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000780-24 Sponsor Protocol Number: 9463-CL-2303 Start Date*: 2012-07-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis
    Medical condition: Neonatal Candidiasis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-021557-40 Sponsor Protocol Number: MM-Rel Start Date*: 2011-03-03
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse
    Medical condition: Multiple mieloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004864-37 Sponsor Protocol Number: ASP-OP3-1 Start Date*: 2018-05-16
    Sponsor Name:Aspen Global Incorporated
    Full Title: A Multinational, Phase 3, Double-blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Ovestin in the Treatment of Symptoms of Vulvar and Vaginal Atrophy in Postmenopausa...
    Medical condition: Vulvovaginal atrophy associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020426-18 Sponsor Protocol Number: IMCLCP12-0922 Start Date*: 2010-10-27
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinom...
    Medical condition: Metastatic gastric or gastroesophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) RO (Completed) FR (Completed) GB (Completed) AT (Completed) LT (Completed) PT (Completed) EE (Completed) IT (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-000864-29 Sponsor Protocol Number: BO17704 Start Date*: 2004-12-01
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recurrent ...
    Medical condition: Advanced or recurrent non-squamous non-small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    PT 10061873 7.0
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000981-46 Sponsor Protocol Number: IC2015-13 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years -
    Medical condition: First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000049-30 Sponsor Protocol Number: RITE-2 Start Date*: 2017-07-26
    Sponsor Name:Medical Enterprises Europe B.V
    Full Title: A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NM...
    Medical condition: Non-Muscle-Invasive Bladder Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 13:00:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA